Piper Sandler analyst Yasmeen Rahimi downgraded CymaBay (CBAY) to Neutral from Overweight with a price target of $32.50, down from $33, following the company’s announcement of its proposed acquisition by Gilead (GILD) for $32.50 per share.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CBAY:
- Gilead acquisition of CymaBay makes sense, says Wells Fargo
- Gilead’s acquisition of CymaBay ‘makes perfect sense,’ says BTIG
- CymaBay downgraded to Market Perform from Outperform at William Blair
- M & A News: Gilead (NASDAQ:GILD) to Acquire CymaBay
- CymaBay jumps 24% to $31.91 after FDA grants priority review for seladelpar